AGP Executive Report
Last update: 2 hours agoRegulation Tightens on Alcohol-Heavy Medicines (India): India’s health ministry moved oral formulations with over 12% ethyl alcohol into stricter Schedule H1 controls, ending prior exemptions for larger bottles and requiring tighter sale and prescription rules. Drug Safety & Supply Scrutiny: Russia’s Rosselkhoznadzor suspended a Dutch veterinary-drug GMP conclusion over suspected non-certified manufacturing sites and missing data responses, while Uttar Pradesh’s FSDA escalated probes into alleged counterfeit medicine networks. Medicare Shake-Ups (US): New 2026 Medicare changes include higher Part B premiums and shifting Medicare Advantage benefits, with more attention on drug pricing and telehealth but added prior-authorization burdens in some areas. Clinical Trial Updates (Oncology): New kidney cancer and muscle-invasive bladder cancer research highlights next steps for chemoimmunotherapy plus intravesical rBCG approaches and ongoing HIF-2 inhibitor development. Public Health Alerts: Health authorities warned people to store medicines safely in heat and avoid hot cars/warm bags, noting risks for common drugs and devices. Healthcare Systems Under Pressure: Uganda’s Kawempe Hospital faced audit criticism for not using e-Afya for vaccine and medicine inventory, amid staff complaints about system usability. Infectious Disease Watch: CDC reported a US humanitarian worker in DR Congo testing positive for Bundibugyo Ebola and is coordinating contact tracing and risk checks.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
